Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects

Trial Profile

Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs XEN 901 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2018 According to a Xenon Pharmaceuticals media release, the Clinical Trial Application (CTA) for XEN901 has been excepted by Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK).
    • 20 Feb 2018 According to a Xenon Pharmaceuticals media release, the first patient has been dosed in this study. Results are anticipated in the second half of 2018.
    • 20 Feb 2018 Status changed from planning to recruiting, according to a Xenon Pharmaceuticals media release .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top